About this trial
Schizophrenia - marked by delusions, hallucinations, and cognitive deficits - causes the most disability of any mental health condition, but existing treatments have significant side effect burden and are often ineffective. Disordered neural activity in the hippocampus likely contributes to schizophrenia symptoms, but to develop better therapies we need to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS). This proposal will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia, offering insights into fundamental hippocampal processes, schizophrenia pathophysiology, and potential avenues to use brain stimulation as a therapeutic tool in this devastating illness.
Eligibility criteria
Qualifiers
Men and women, ages 18 to 65 years
Medically intractable epilepsy requiring phase II monitoring (intracranial EEG arms only)
DSM-V diagnosis of schizophrenia spectrum Axis I disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive TMS-EEG arms only).
Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent
Disqualifiers
DSM5 diagnosis of intellectual disability
Significant head injury
Active suicidal ideation or history of suicide attempt within the past 1 year.
Medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition.
Trial design
Treatments tested in this trial
- Intracranial electrodes
- TMS
- TMS sham
Treatment groups
Locations
1Sponsors and collaborators
Stanford University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator